Journal
JOURNAL OF ORGANIC CHEMISTRY
Volume 76, Issue 8, Pages 2594-2602Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jo102471r
Keywords
-
Categories
Funding
- Sanofi-Aventis
Ask authors/readers for more resources
SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). Different strategies have been studied to synthesize this molecule and among the strategies an organo-catalyzed Henry reaction, applied to an a.-keto ester, has produced SSR 241586 in excellent enantiomeric excess.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available